FLP Wealth Management’s Royalty Pharma RPRX Stock Holding History

FLP Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-540	Closed	-$13.8K	–	363
2024 Q4	$13.8K	Buy	+540	New	+$14.3K	0.04%	207

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLP Wealth Management's RPRX Position: Q1 2025 in Review

FLP Wealth Management sold out of Royalty Pharma (RPRX) in Q1 2025, closing a stake of 540 shares — an estimated $13.8K sold.

FLP Wealth Management first reported a position in RPRX in Q4 2024 and held it in 1 quarter. The position peaked at $13.8K in Q4 2024. 447 funds tracked by Wall St. Rank hold RPRX as of Q1 2025.

FLP Wealth Management reported no remaining Royalty Pharma position as of Q1 2025 after selling out during the quarter.
FLP Wealth Management sold 540 Royalty Pharma shares in Q1 2025, an estimated $13.8K.
FLP Wealth Management first reported a position in Royalty Pharma in Q4 2024 and held it in 1 quarter.
FLP Wealth Management's Royalty Pharma position peaked at $13.8K in Q4 2024.
447 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2025.

Based on FLP Wealth Management's 13F filing for Q1 2025, filed 15 Jul 2025.